Avant Technologies and Ainnova in Talks to Obtain Innovative Technology in Preventative Health Reporting

Rhea-AI Summary

Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech are in negotiations to license or acquire patented early disease detection technology from an international healthcare innovation company. The potential deal aims to enhance preventive health reporting capabilities and disease detection correlation without requiring complete patient data. The companies are building their technology portfolio through their AI-driven Vision AI platform, with a focus on making early disease detection more accessible and affordable. They have already integrated four algorithms through exclusive licensing and view retinal examination as a new vital sign, combined with laboratory tests and patient data for comprehensive health reporting.

Positive

• Potential acquisition or licensing of patented early disease detection technology
• Existing successful integration of four algorithms into Vision AI platform
• Strategic expansion of technology portfolio in preventive healthcare
• Focus on accessible and low-cost preventive healthcare solutions

Negative

• Deal is still in early discussion phase with no guaranteed outcome
• Financial terms and potential costs not disclosed
• Timeline for potential deal completion not specified

LAS VEGAS, May 20, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies are in talks with an international healthcare innovation company to license or potentially acquire its patented early disease detection technology.  If successful, it's a global license or acquisition that has the potential to revolutionize preventive health reporting and to generate correlations for future detection of new diseases without the need for all the patient's data.

Avant and Ainnova continue to grow the footprint and capabilities of their technology portfolio with the goal of being a leader in early disease detection using the Company's signature AIdriven Vision AI technology platform.   

Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said of the Company's aim to continue to add to its portfolio, "Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily.  We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem.

"To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions."  

Avant and Ainnova see the retina as a new vital sign, but also understand that leveraging the results of laboratory tests and basic patient data can all work in concert to provide a comprehensive health report.

Vargas added, "We have already integrated an exclusive license for four algorithms into our Vision AI platform, and we are now in talks to license and potentially acquire an innovative technology that would be a game changer in our industry."

Avant will inform its shareholders of any updates at an appropriate time.

About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

About Avant Technologies, Inc. 
Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare.  With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

More information about Avant can be found at https://avanttechnologies.com

You can also follow us on social media at:
https://twitter.com/AvantTechAI https://www.linkedin.com/company/avant-technologies-ai 
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI

Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements."  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact.  Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.

Contact:
Avant Technologies, Inc.
info@avanttechnologies.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avant-technologies-and-ainnova-in-talks-to-obtain-innovative-technology-in-preventative-health-reporting-302460374.html

SOURCE Avant Technologies Inc.

FAQ

What is the potential acquisition target for Avant Technologies (AVAI) in 2025?

Avant Technologies and Ainnova Tech are in talks with an international healthcare innovation company to license or acquire its patented early disease detection technology.

How many algorithms has AVAI already integrated into their Vision AI platform?

Avant Technologies has already integrated four algorithms through exclusive licensing into their Vision AI platform.

What is the main focus of Avant Technologies' disease detection technology?

The company focuses on early disease detection using AI-driven Vision AI technology, viewing retinal examination as a vital sign combined with laboratory tests and patient data for comprehensive health reporting.

What is the partnership structure between Avant Technologies and Ainnova Tech?

Avant Technologies and Ainnova Tech are joint venture partners operating through Ai-nova Acquisition Corp., with Ainnova's CEO Vinicio Vargas serving on the joint venture's board of directors.

What is the goal of AVAI's preventive health technology?

The goal is to make early disease detection accessible and affordable, allowing patients to get preventive check-ups anywhere at a low cost, and prevent the development of diseases that could be avoided.